Latest News

Date Title Topic
15 Feb 2017 First-Line Treatment of EGFR and ALK Wild-Type Advanced/Metastatic NSCLC: Refined Endpoints and Statistical Analysis Plan in the Phase III MYSTIC Study Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
14 Feb 2017 European Patent Office Decision on Dasatinib Haematologic malignancies - Anticancer agents & Biologic therapy
14 Feb 2017 ESMO Awards: Now Open for Nominations
13 Feb 2017 Now Available in Polish, the ESMO/ACF Patient Guide on NSCLC
13 Feb 2017 European Commission Approves Pembrolizumab for First-Line Treatment of Patients with Metastatic NSCLC Whose Tumours Have High PD-L1 Expression with No EGFR or ALK Positive Tumour Mutations Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
10 Feb 2017 6th ICHNO Congress: Register now!
10 Feb 2017 Launch of the New Cobas m 511 Analyser Marks a New Era in Haematology Testing Haematologic malignancies
09 Feb 2017 Pre-IMPAKT 2017 Training Course: Apply Today!
09 Feb 2017 Press Release: ESMO Announces New Award for Achievements in Immune-Oncology
09 Feb 2017 Media Alert: ESMO Summit Africa 2017
08 Feb 2017 Our Patient Guide in Breast Cancer Is Now Available Also in Polish
08 Feb 2017 Our Patient Guide on Ovarian Cancer is Now Available in Russian
07 Feb 2017 Now Available in Polish, the ESMO/ACF Patient Guide on Colorectal Cancer
07 Feb 2017 ESMO Preceptorship on Neuroendocrine Neoplasms
07 Feb 2017 Withdrawal of the Marketing Authorisation Application for Zioxtenzo (Pegfilgrastim) Palliative and supportive care